Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?

Adenocarcinoma (AC) is the most common type of primary pulmonary malignancy. Lung carcinoid, however, is a rare neuroendocrine tumor. Their coexistence is extremely uncommon. We report the unique case of synchronous advanced lung AC of the right upper lobe (stage IIIB) and typical endobronchial carc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anti-cancer drugs 2018-03, Vol.29 (3), p.281-285
Hauptverfasser:	Gordana, Drpa, Sreter, Katherina B, Spomenka, Manojlovic, Suzana, Kukulj
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - enzymology Adenocarcinoma - genetics Adenocarcinoma of Lung Antineoplastic Agents - therapeutic use Bronchial Neoplasms - drug therapy Bronchial Neoplasms - enzymology Bronchial Neoplasms - genetics Carcinoid Tumor - drug therapy Carcinoid Tumor - enzymology Carcinoid Tumor - genetics ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Erlotinib Hydrochloride - therapeutic use Humans Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - genetics Male Middle Aged Mutation Neoplasms, Multiple Primary - drug therapy Neoplasms, Multiple Primary - enzymology Neoplasms, Multiple Primary - genetics Protein Kinase Inhibitors - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!